Wen-liang Wang

发表

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.

Qingsong Liu, X. Liu, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.

Qingsong Liu, Xiaofei Liang, Q. Liu, 2021, Journal of medicinal chemistry.

Introduction of G1 phase arrest in Human Hepatocellular carcinoma cells (HHCC) by APMCF1 gene transfection through the down-regulation of TIMP3 and up-regulation of the CDK inhibitors p21

Jing Zhang, Li Wang, Zhipei Zhang, 2006, Molecular Biology Reports.

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Zhenquan Hu, Q. Liu, Hong Wu, 2017, Journal of medicinal chemistry.

Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.

Qingsong Liu, Zhenquan Hu, Q. Liu, 2018, European journal of medicinal chemistry.

Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2019, Cancer letters.

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

Qingsong Liu, Zhenquan Hu, Cheng Chen, 2021, European journal of pharmacology.

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Q. Liu, Zong-ru Jiang, Cheng Chen, 2020, Acta Pharmacologica Sinica.

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Zong-ru Jiang, Cheng Chen, Ao-li Wang, 2020, Acta Pharmacologica Sinica.

Application of High-Efficiency Cell Expansion and High-Throughput Drug Sensitivity Screening for Leukemia Treatment

Lili Li, R. Xia, Jian Ge, 2022, Disease markers.

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.

Qingsong Liu, Cheng Chen, Ao-li Wang, 2020, Experimental cell research.

All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase.

Qingsong Liu, Zong-ru Jiang, Juan Liu, 2020, Cancer letters.

Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models

Q. Liu, Hong Wu, Zong-ru Jiang, 2019, Investigational New Drugs.

Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2020, Journal of medicinal chemistry.

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

X. Liu, Q. Liu, Zong-ru Jiang, 2019, Acta pharmaceutica Sinica. B.

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes.

Q. Liu, Ao-li Wang, F. Zou, 2022, Journal of medicinal chemistry.

Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium.

Zhenquan Hu, Q. Liu, Xiaofei Liang, 2019, European journal of medicinal chemistry.

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

Zhenquan Hu, Q. Liu, Hong Wu, 2019, Cancer biology & therapy.

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.

Q. Liu, Chen Hu, F. Zou, 2023, European journal of medicinal chemistry.